Adicet Bio reported a net loss of $26.9 million for Q3 2025, an improvement from $30.5 million in Q3 2024. The company's R&D and G&A expenses both decreased, contributing to the reduced loss. Adicet also announced positive preliminary safety and efficacy data from its Phase 1 clinical trial of ADI-001 in lupus nephritis and systemic lupus erythematosus, and successfully raised $74.8 million in net proceeds from a registered direct offering, extending its cash runway into the second half of 2027.

Adicet Bio reported a net loss of $28.2 million for Q1 2025, a slight increase from $28.0 million in Q1 2024. The company's cash and cash equivalents stood at $150.4 million, and it expects this to fund operations into the second half of 2026. Key operational highlights include ongoing patient enrollment in Phase 1 trials for ADI-001 in autoimmune diseases and ADI-270 in ccRCC, with preliminary data expected in 2H/2025.

Adicet Bio reported a net loss of $28.7 million for Q4 2024, an improvement from a $29.5 million net loss in Q4 2023. The company's cash position increased to $176.3 million, and it expects current funds to last into the second half of 2026. R&D expenses decreased, while G&A expenses saw a slight increase.

Adicet Bio reported a net loss of $30.5 million for the third quarter of 2024, with cash, cash equivalents, and short-term investments totaling $202.1 million as of September 30, 2024. The company is advancing its clinical pipeline, including ADI-001 for autoimmune diseases and ADI-270 for solid tumors.

Adicet Bio reported a net loss of $29.9 million for the second quarter of 2024, with cash and cash equivalents totaling $224.1 million as of June 30, 2024. The company is advancing its pipeline of allogeneic gamma delta T cell therapies, including ADI-001 for autoimmune diseases and ADI-270 for renal cell carcinoma.

Adicet Bio reported a net loss of $28.0 million for the first quarter of 2024, with cash and cash equivalents totaling $247.6 million as of March 31, 2024. The company is on track to initiate a Phase 1 clinical trial evaluating ADI-001 in lupus nephritis in 2Q 2024 and presented preclinical data on ADI-270 at the ASGCT Annual Meeting.

Adicet Bio reported a net loss of $29.5 million for the fourth quarter of 2023, with R&D expenses at $24.8 million and G&A expenses at $6.8 million. The company highlighted the FDA clearance for ADI-001 in lupus nephritis and progress in advancing ADI-270 preclinical development. They extended their projected cash runway into 2H 2026.

Adicet Bio reported a net loss of $49.9 million for the third quarter of 2023, including a goodwill impairment expense of $19.5 million. The company is focusing on advancing ADI-001 and ADI-270, with plans to file an IND for ADI-270 in the first half of 2024. Cash and cash equivalents were $183.3 million as of September 30, 2023, expected to fund operations into the first half of 2025.

Adicet Bio reported a net loss of $32.4 million for the second quarter of 2023, with research and development expenses increasing to $28.4 million. The company's cash and cash equivalents totaled $205.5 million as of June 30, 2023, expected to fund operations into the first half of 2025. Clinical development continues with ADI-001, ADI-925 and ADI-270.

Adicet Bio reported a net loss of $30.9 million for the first quarter of 2023, with cash and cash equivalents totaling $231.6 million as of March 31, 2023. The company is on track to report additional data and provide a regulatory update for ADI-001 in the second quarter of 2023 and plans to initiate a pivotal study in the fourth quarter of 2023.

Adicet Bio reported a net loss of $29.9 million for the fourth quarter of 2022, compared to a net loss of $15.8 million for the same period in 2021. Research and development expenses increased to $25.0 million, and general and administrative expenses were $6.6 million. The company's cash and cash equivalents totaled $257.7 million as of December 31, 2022.

Adicet Bio reported its Q3 2022 financial results, highlighting encouraging clinical progress with ADI-001 and a strong cash position of $282.7 million, expected to fund operations into the first half of 2025.

Adicet Bio reported positive clinical data from ADI-001, received FDA Fast Track Designation, and has a strong balance sheet with $304.3 million in cash and cash equivalents. The company is on track to potentially initiate at least one pivotal study during the first half of 2023 and expects to meet several meaningful milestones along the way, including during the second half of this year.

Adicet Bio reported a net income of $4.6 million for the first quarter of 2022, which includes non-cash stock-based compensation expense of $4.4 million, and cash and cash equivalents of $277.9 million as of March 31, 2022.

Adicet Bio announced positive interim clinical data from Phase 1 study ADI-001 and successfully raised $94.2 million in net proceeds through a public follow-on offering. Net loss for the quarter was $15.8 million.

Adicet Bio reported its Q3 2021 financial results, highlighting progress in the ADI-001 Phase 1 trial and a new collaboration with Twist Bioscience. The company's net loss was $14.0 million, and it had $192.2 million in cash and cash equivalents.

Adicet Bio reported its Q2 2021 financial results, highlighting the initiation of the Phase 1 trial of ADI-001 in non-Hodgkin’s lymphoma and the completion of a successful capital raise. The company's cash position is expected to fund operations through the beginning of the second half of 2023.

Adicet Bio reported financial results for the first quarter ended March 31, 2021. The company successfully raised $143.8 million in net proceeds and initiated the Phase 1 trial of ADI-001 for NHL treatment.

Adicet Bio reported a net loss of $9.0 million for the fourth quarter of 2020, compared to a net loss of $6.6 million for the same period in 2019. The company's cash, cash equivalents and marketable debt securities were $94.6 million as of December 31, 2020, as compared to $62.4 million as of December 31, 2019.

Adicet Bio reported a net loss attributable to common shareholders of $14.8 million for the third quarter ended September 30, 2020. The company's cash and cash equivalents and marketable debt securities were $108.1 million as of September 30, 2020. They also completed a merger with resTORbio and received a $10 million product development milestone payment from Regeneron.

resTORbio reported a net loss of $5.6 million, or $0.15 per share, for the three months ended June 30, 2020. The company's cash and cash equivalents were $70.9 million as of June 30, 2020. They also entered into a definitive merger agreement with Adicet Bio to advance allogeneic gamma delta CAR-T cell technology.

resTORbio reported a net loss of $7.0 million, or $0.19 per share, for the first quarter ended March 31, 2020. The company's cash, cash equivalents, and marketable securities totaled $76.3 million as of March 31, 2020. A merger agreement with Adicet Bio was announced to advance allogeneic gamma delta CAR-T cell therapy.

resTORbio reported a net loss of $28.9 million for the fourth quarter of 2019, with R&D expenses at $26.1 million and G&A expenses at $3.3 million. The company's cash, cash equivalents, and marketable securities totaled $91.5 million as of December 31, 2019. The company is focusing on its Phase 1b/2a trial of RTB101 in Parkinson's disease and exploring strategic alternatives to enhance shareholder value.